ARTICLE | Company News
Foundation Medicine Inc. (NASDAQ:FMI), DIAN Diagnostics Group Co. Ltd. (SZSE:300244) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to integrate Foundation Medicine's suite of genomic profiling (CGP) tests into clinical patient care in China. The tests include FoundationOne, FoundationACT and FoundationOne Heme.
Under the deal, DIAN will be the exclusive provider of sequencing services for the suite and Roche will commercialize the diagnostics in China. The pharma has rights to the tests under a 2015 deal (see BioCentury, Jan. 19, 2015)...